Michael D Howell is a prominent inventor based in Kennett Square, PA (US). He has made significant contributions to the field of medicine, particularly in the development of treatments for various conditions. With a total of 16 patents to his name, Howell's work has had a substantial impact on patient care.

Latest Patents

Among his latest patents is a formulation of Ruxolitinib aimed at reducing itch in patients with atopic dermatitis. This innovative disclosure relates to methods of alleviating itch in patients suffering from this condition by administering a topical cream containing either 0.75% or 1.5% Ruxolitinib two times per day. Another notable patent involves biomarkers for graft-versus-host disease, which are predictive of a subject's responsiveness to a JAK inhibitor. These biomarkers, along with the associated compositions and methods, are instrumental in selecting appropriate treatment modalities for individuals who have, are suspected of having, or are at risk of developing Graft-Versus-Host Disease.

Career Highlights

Michael D Howell is currently associated with Incyte Corporation, where he continues to push the boundaries of medical innovation. His work at Incyte has allowed him to collaborate with other talented professionals in the field, further enhancing the impact of his inventions.

Collaborations

Howell has worked alongside notable colleagues such as Kang Sun and Jim Lee, contributing to a collaborative environment that fosters innovation and progress in medical research.

Conclusion

Michael D Howell's contributions to the field of medicine through his patents and collaborations highlight his dedication to improving patient outcomes. His innovative work continues to pave the way for advancements in treatment options for various medical conditions.

This text is generated by artificial intelligence and may not be accurate.